535 W 24TH STREET, NEW YORK, NY
Neurogene Inc. Enters Underwriting Agreement for $105 Million Offering
Investor Presentation
Reg. FD
2026 Annual Meeting Results - Election of Directors Robert Baffi and Rohan Pa...
Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Late Filing for Quarterly Report
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement